News

Filter

Current filters:

RegulationBiosimilars

1 to 9 of 68 results

Farmaindustria defends the non-interchangeability principle for biologic and biosimilar medicines

21-03-2015

Speaking at the first Biological Medicines Forum organized by the Associations last week, the president…

BiosimilarsBiotechnologyPatents & Trade marksRegulationSpain

Samsung Bioepis seeks EMA approval of Remicade biosimilar SB2

13-03-2015

South Korea-based Samsung Bioepis, a joint venture between Samsung and US biotech firm Biogen Idec, says…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsEuropeGenericsJohnson & JohnsonRegulationRemicadeSamsung BioepisSB2

Prime Therapeutics welcomes FDA's approval of first biosimilar in USA, but says more clarity is needed

Prime Therapeutics welcomes FDA's approval of first biosimilar in USA, but says more clarity is needed

09-03-2015

Prime Therapeutics, a non-profit US pharmacy benefit manager serving more than 26 million members, has…

AmgenBiosimilarsBiotechnologyNeupogenNovartisOncologyRegulationSandozUSAZarxio

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

06-03-2015

Sandoz, the generics unit of Swiss pharma giant Novartis, today received approval from the US Food and…

AmgenBiosimilarsBiotechnologyNeupogenNovartisOncologyRegulationSandozUSAZarxioZarzio

US biosimilar approvals poised to grow, but market uptake faces challenges, says Tufts CSDD

05-03-2015

Biosimilar approvals in the USA are expected to increase during the next five years, but safety concerns…

BiosimilarsBiotechnologyFinancialMarkets & MarketingRegulationUSA

European generics group launches Code of Conduct

05-03-2015

Following the adoption of the European Commission Guiding Principles Promoting Good Governance in the…

BiosimilarsEuropeGenericsMarkets & MarketingRegulation

Biosimilars viable only for biologics with sales of $898 million, says Prime Therapeutics report

Biosimilars viable only for biologics with sales of $898 million, says Prime Therapeutics report

26-02-2015

Although there is widespread optimism around the first biosimilars being launched in the USA, a new report…

BiosimilarsProductionRegulationUnited StatesUSA

Intas becomes first Indian company to launch biosimilar in the EU

Intas becomes first Indian company to launch biosimilar in the EU

23-02-2015

Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated…

BiosimilarsBiotechnologyFilgrastimHematologyImmunologicalsIndiaIntas PharmaceuticalsMarkets & MarketingRegulation

1 to 9 of 68 results

Back to top